GoodRx Holdings Inc. (GDRX) PT Raised to $10 at JPMorgan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- AMD gets bullish pre-earnings call from Lynx as server CPU demand accelerates
- Marathon Petroleum to sell two refineries to CVR Energy for $4.2B
- Moderna shares rise ahead of Thursday earnings report
- AMD forecast eases AI spending fears as data-center sales surge
- Broadcom shares climb as AI chip financing deal supports rally
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
GoodRx (GDRX) Erupts 40% on Mixed Results but Analysts Praise Better Visibility
August 9, 2022 8:10 AM EDTShares of GoodRx (NASDAQ: GDRX) are up about 40% in premarket trading Tuesday after the company reported decent Q2 results and resolved the dispute between its pharmacy benefit management customers and Kroger.
The telemedicine company reported Q2 adjusted EPS of 6c, down from 8c in the year-ago period, and above the analyst consensus of 4c per share. GDRX reported second-quarter revenue of $191.8 million, up 8.6% YoY and topping the consensus projection of $184.9... More



